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Prolyl-isomerase Pin1 controls Notch3 protein expression and
regulates T-ALL progression
G Franciosa1, G Diluvio1, F Del Gaudio1, MV Giuli1, R Palermo2, P Grazioli1, AF Campese1, C Talora1, D Bellavia1, G D’Amati3,
ZM Besharat1, C Nicoletti4, CW Siebel5, L Choy5, A Rustighi6,7, G Del Sal6,7, I Screpanti1,2,8 and S Checquolo9
Deregulated Notch signaling is associated with T-cell Acute Lymphoblastic Leukemia (T-ALL) development and progression. Increasing
evidence reveals that Notch pathway has an important role in the invasion ability of tumor cells, including leukemia, although the
underlying molecular mechanisms remain mostly unclear. Here, we show that Notch3 is a novel target protein of the prolyl-isomerase
Pin1, which is able to regulate Notch3 protein processing and to stabilize the cleaved product, leading to the increased expression of the
intracellular domain (N3IC), finally enhancing Notch3-dependent invasiveness properties. We demonstrate that the combined inhibition
of Notch3 and Pin1 in the Notch3-overexpressing human leukemic TALL-1 cells reduces their high invasive potential, by decreasing the
expression of the matrix metalloprotease MMP9. Consistently, Pin1 depletion in a mouse model of Notch3-induced T-ALL, by reducing
N3IC expression and signaling, impairs the expansion/invasiveness of CD4
+CD8+ DP cells in peripheral lymphoid and non-lymphoid
organs. Notably, in in silico gene expression analysis of human T-ALL samples we observed a significant correlation between Pin1 and
Notch3 expression levels, which may further suggest a key role of the newly identified Notch3-Pin1 axis in T-ALL aggressiveness and
progression. Thus, combined suppression of Pin1 and Notch3 proteins may be exploited as an additional target therapy for T-ALL.
Oncogene (2016) 35, 4741–4751; doi:10.1038/onc.2016.5; published online 15 February 2016
INTRODUCTION
Notch pathway is an evolutionarily conserved signaling pathway,
which has an important role in cell-fate determination and
differentiation in many tissues.1 Aberrant Notch signaling has
been involved in the pathogenesis of human diseases,2 including
T-cell acute lymphoblastic leukemias (T-ALLs), which represents
approximately 15 and 25% of ALLs seen in children and adults,
respectively.3,4 Constitutive activation of either Notch1 or Notch3
is able to induce efficiently T-ALL in mouse models, closely
resembling their human counterparts.5–8 Activating mutations in
Notch1 have been identified in over 60% of human T-ALL,9,10
whereas Notch3 overexpression has been shown in most human
T-ALL samples.8,11 The absence of Notch3 genetic modifications in
T-ALL implies that other mechanisms such as transcriptional,
epigenetic, post-translational or a combination of these are
responsible for its overexpression. Altered degradation process
and/or acetylation/deacetylation balance have been shown to have
an important role in the control of Notch3 protein stability,12,13 thus
contributing to the sustained Notch3 overexpression and Notch3-
dependent leukemia development in Notch3 transgenic mice.7 These
observations suggest that Notch3 expression can be modified by
more than one type of post-translational modification (PTM) event.14
Increasing evidence reveals a key role of PTMs in the initiation,
development and progression of several diseases, including
cancer.10 Reversible phosphorylation, that is, addition of a phosphate
group to the serine, threonine and tyrosine residues is a ubiquitous
regulatory mechanism and was one of the first PTMs to be
described. The peptidyl-prolyl Pin1 cis/trans isomerase was
discovered as an enzyme that specifically recognizes and binds to
phosphorylated Serines or Threonines preceding a Proline (phospho
Ser/Thr-Pro) residue inducing conformational changes of phospho-
proteins.15 Pin1 is a unique prolyl-isomerase that transduces
phosphorylation signaling by affecting the functions of its substrates,
including protein stability, catalytic activity, phosphorylation status,
protein–protein interactions and/or subcellular localization.15–17 Pin1
alterations have been implicated in the amplification of oncogenic
signals, by stabilizing oncoproteins and/or destabilizing or inactivat-
ing tumor suppressors,15,18 as also shown by its frequent deregulation
in several human malignancies.16 Moreover, recent studies suggested
a pivotal role of Pin1 in increasing the oncogenic activity of Notch1
protein in breast cancer development and progression.19,20 However,
whether Pin1 might directly act on Notch expression and/or function
in leukemias is not known. To this end, we evaluated the possible
crosstalk between Pin1 and Notch proteins in T-ALL context,
by analyzing human T-ALL cell lines and a mouse model of
Notch3-induced T-ALL.7 Here, we show that Notch3 is a novel target
of Pin1 isomerase. The Notch3-Pin1 binding regulates Notch3 protein
expression and signaling, through a dual mechanism that impinges
on its cleavage at the cell membrane and on the stability of its
released intracellular domain. Notably, Pin1 deletion in N3IC-tg mice
prevents the acquisition of an invasive malignant phenotype of T-ALL.
Together, our findings demonstrate that Pin1–Notch3 axis may
reinforce Notch signaling effect in T-ALL, by influencing tumor
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grade and aggressiveness, finally suggesting that their combined
inhibition may be exploited in target therapy protocols.
RESULTS
Pin1 regulates Notch3 expression in T-ALL cell lines
To analyze the putative role of Pin1 isomerase on both Notch1
and Notch3 protein expression and function in T-ALL context, Pin1
expression was silenced in different human T-ALL cell lines (Molt3,
SilAll, P12-Ichikawa and Jurkat), all constitutively expressing
activated Notch1-IC (N1Val1744) and Notch3-IC (N3IC) as shown in
Figures 1b and c, respectively. The efficiency of Pin1 silencing was
evaluated by western blot of Pin1 (Figure 1a). In the absence of
Pin1, the levels of activated Notch1-IC are variably affected,
appearing increased in SilAll and Jurkat cells, whereas decreased
in Molt3 and P12-Ichikawa cells (Figure 1b), highlighting the lack
of correlation between high Pin1 levels and the upregulation
of Notch1-IC protein levels in human T-ALL cells, as instead
previously described in breast cancer.19,20 Notably, the levels
of N3IC decreased in all the cell lines analyzed, independently of
Notch1 activation status, as revealed by the immunoreactivity to
the anti-Notch1Val1744 antibody (Figure 1c). This is also evident in
Pin1-silenced TALL-1 cells (Figures 1d, f and g), which neither bear
Notch1-activating mutations nor display Notch1 activation21 and
Figure 1e), while displaying constitutive activation of Notch3,22 also
confirmed by the immunoreactivity to the specific anti-N3IC-act
antibody (Figure 1g). Taken together, these results suggest that Pin1
knockdown may have a specific role upon Notch3 protein in T-ALL
context. Furthermore, we performed an in silico analysis of the
Notch3 and Pin1 gene expression levels in several T-ALL cell
lines23–25 (Supplementary Figure 1a and Supplementary Table S1)
and in a cohort of 117 T-ALL pediatric patients26 (Supplementary
Figure 1b). The analysis highlighted a significant direct correlation
between Pin1 and Notch3 gene expression levels, allowing us to
hypothesize a possible direct relationship between Pin1 and Notch3
at the protein level in T-ALL context.
Combined inhibition of Pin1 and Notch3 results in a reduced
T-ALL invasiveness
Digging deeper into the effects of Pin1 depletion in leukemic cells,
we focused our in vitro study on the Notch3-overexpressing
TALL-1 leukemic cells,22 described above. We first evaluated
whether the absence of Pin1 could affect cell growth or viability
in such cells (Figure 2a and Supplementary Figure 2a). Despite the
decreased N3IC expression levels previously observed (Figures 1f
and g), Pin1 seems not to be required for TALL-1 cell growth
(Supplementary Figure 2a). Next, we focused on TALL-1 invasive
properties, since it has been demonstrated that high levels
of Pin1 correlate with high tumor grade and aggressiveness in
breast cancer.27 By using matrigel-coated invasion chambers
to simulate extracellular matrix, known to be degraded during
tumor dissemination,28 we observed a significant decrease
in the invasion of Pin1-silenced TALL-1 cells when compared
with the control cells (Figure 2b, left panel). Notably, this
reduction correlates with the decrease in the pro-invasive
matrix metalloproteinase MMP9 expression levels (Figure 2b,
right panel), known to be involved in the extracellular
matrix degradation, thus promoting tumor progression.29,30
Furthermore, as shown in Figure 2c, when Pin1 silencing was
combined with Notch3 blocking, we observed a significantly
Figure 1. Pin1 silencing modulates the Notch3 protein expression in human T-ALL cell lines. Activated Notch1 (Notch1Val1744) and Notch3
(N3IC) expression in response to Pin1 silencing in (b, c) Notch1-activated (Molt3, SilAll, P12-Ichikawa and Jurkat) and (e–g) Notch1-non
activated/Notch3 activated (N3IC-act) overexpressing (TALL-1) human T-ALL cell lines. (a, d) Western blots against Pin1 show the efficiency of
Pin1 silencing (siPin1) (left panels). Western blot against the anti-β-actin was used as a loading control. All the western blots in the figure are
representative of at least three independent experiments, each in triplicate. In all right (a–d) and lower (f, g) panels are shown the optical
densitometry (OD) of Pin1 (a, d), Notch1 (b) and Notch3 (c, f, g) protein expression levels analyzed in all the experiments performed, thus
including the P-values, calculated using Student’s T-test (i.e., ns, not significant P40.05; *P⩽ 0.05; **P⩽ 0.01).
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higher decrease in the activated-N3IC protein levels with respect
to control cells, or Pin1 or Notch3 singly inhibited (Figure 2c).
Notably, the combined inhibition further reduced the MMP9 mRNA
expression (Figure 2d), thus supporting the notion that Notch3 and
Pin1 synergistically contribute to invasive properties of leukemic
cells, without influencing their viability (Supplementary Figure 2b).
Deletion of Pin1 correlates with the significant decrease in Notch3
protein expression and function in vivo
To deepen the study of the relationship between Pin1 and Notch3
in vivo, we utilized the Notch3-IC transgenic mice (N3IC-tg), a mouse
model of Notch3-dependent T-ALL we previously generated,7
which overexpress constitutively activated Notch3-IC protein and
lack the expression of the activated Notch1 protein (Figure 3b and
Pelullo et al.31), thus resembling the leukemic human cell line
TALL-1 (Figures 1e–g).21,22 We generated double mutant mice (N3IC-
tg/Pin1− /−) by intercrossing the N3IC-tg mice with the Pin1
knockout mice (Pin1− /−).32
Figure 3a shows that in N3IC-tg/Pin1
− /− and N3IC-tg young
mice (6 weeks) the thymocyte subset distribution is similar with
respect to CD4 and/or CD8 expression. However, the Pin1 ablation
in N3IC-tg mice, confirmed by the absence of the Pin1 protein
expression in double mutant thymocytes (Figure 3b, left panel),
caused a significant reduction in the Notch3-IC protein expression
levels in whole thymocyte extracts derived from N3IC-tg/Pin1
− /−
mice when compared with N3IC-tg littermates (Figure 3b, left
panel), as revealed by the western blot with either anti-N3IC-act
or anti-HA antibodies, the latter recognizing the HA-tagged N3IC
transgene. Consistently, we also observed decreased protein
expression levels of known Notch target genes, such as
Hes133 and pTalpha,34 when compared with N3IC-tg thymocytes
(Figure 3b, right panel). Notably, neither Notch3-IC tg nor double
mutant N3IC-tg/Pin1
− /− mice display activated Notch1 protein
(Figure 3b, right panel).
We and others have previously shown that accumulation
of CD4+CD8+ DP cells in spleen (SPL), lymph nodes and peripheral
blood (PB) represents a pathognomonic feature of T-cell leukemias
sustained by enforced expression of NIC in pre-T-cells or in bone
marrow of mice.5,7 As shown in Figure 3c, upper panels, and
Supplementary Figure 3a, DP cells appeared in the SPL of 6-week-
old double mutant N3IC-tg/Pin1
− /− mice in a similarly increased
percentage with respect to N3IC-tg littermates, when compared
with wt (Pin1+/+) mice. On the contrary, in circulating blood of
double mutant mice the percentage of DP cells was similar to that
observed in wt mice, while being increased in N3IC-tg littermates
(Figure 3c, lower panels, and Supplementary Figure 3b). Notably,
similarly to what observed in thymocytes, Pin1-deleted DP
transgenic splenocytes revealed a strong decrease in N3IC protein
levels, as revealed by the western blot performed on DP sorted
cells (Figure 3d). These results, together with the in vitro results
described above (Figure 2), suggest the possibility that Pin1
deletion in N3IC-tg mice, by decreasing N3IC expression and
signaling, could inhibit Notch3-IC-dependent tumor progression.
In keeping with this, ablation of endogenous Pin1 significantly
reduced DP sorted splenocytes cell invasiveness, measured in
Matrigel invasion assay (Figure 3e), while their apoptotic or
proliferative rate did not change (data not shown).
Deletion of Pin1 prevents T-ALL progression in Notch3-IC tg mice
To better address the role of Pin1–Notch3 axis in sustaining
lymphoma cell migration/invasion and tumor progression, we
analyzed the lymphoma development by evaluating the total cell
yield and immunophenotype of SPL, lymph nodes and blood of
double mutant N3IC-tg/Pin1
− /− mice with respect to N3IC-tg
littermates (Figure 4a). The absence of DP cells in SPL, mesenteric
lymph nodes and PB of wt mice represents the physiological
condition in the absence of tumor (Figure 4a, left panels, and
Supplementary Figures 3c–e). The analysis of different peripheral
lymphoid tissues obtained from 10-week-old double mutant
N3IC-tg/Pin1
− /− mice, age at which a massive presence of DP
cells is usual in N3IC-tg mice (Figure 4a, middle panels, and
Supplementary Figures 3c–e), showed the presence of a significantly
reduced percentage of DP cells in SPL and lymph nodes (11.65 and
4.55% vs 30, 28 and 34.54%, respectively) (Figure 4a, right and
middle panels, and Supplementary Figures 3c and d). Moreover,
DP cells are almost absent (0.99%) in circulating blood of double
mutant mice, while amounting to 17.18% in N3IC-tg littermates
(Figure 4a, right and middle panels, and Supplementary Figure 3e).
More importantly, N3IC-tg/Pin1
− /− double mutant mice never show
neither splenomegaly nor other overt macroscopic or histological
abnormalities of peripheral lymphoid organs, like commonly
observed in N3IC-tg littermates (Figures 4b and c and data not
shown). Consistently, while the non-lymphoid organs (liver and
lung) of N3IC-tg mice showed a massive and diffuse tumor cell
infiltration (Figure 4d, middle panels), already evident at 10 weeks
of age, the N3IC-tg/Pin1
− /− double mutant mice only display a little
lymphoid cell infiltration around the vessels, restricted to the liver
at late age (Figure 4d, right panels).
Figure 2. Pin1 silencing influences the TALL-1 cells invasiveness by
regulating N3IC protein expression. (a) Western blots against Pin1
show the efficiency of Pin1 silencing in TALL-1 cell line (siPin1).
(b) TALL-1 cell line silenced or not for Pin1 was used in invasion
Matrigel assay: relative percentage of invasiveness is shown with
respect to the negative control, siCTR (left panel). RT–PCRs show
downmodulation of MMP9 mRNA expression in Pin1-silenced cells
(siPin1) with respect to the control cells (siCTR) (right panel).
(c) Western blots against activated-N3IC protein (N3IC-act) and Pin1
show the efficiency of the Notch3 receptor block and Pin1 silencing,
respectively (lower panels). Optical densitometry (OD) of the
activated-N3IC protein expression (upper panel). (d) RT–PCRs show
downmodulation of MMP9 mRNA expression in Notch3-blocked
Pin1-silenced cells (siPin1+FCNotch3) with respect to both Notch3-
blocked or Pin1-silenced controls alone. In both panels (a) and (c),
western blot against the anti-β-actin was used as a loading control.
All the results shown in the figure are expressed as the means
average deviations of three separate experiments, each in triplicate,
and P-values were calculated using Student’s T-test (i.e., ns, not
significant P40.05; *P⩽ 0.05; **P⩽ 0.01). WCEs, whole-cell extracts.
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Moreover, such a huge difference in phenotype observed
between N3IC-tg/Pin1− /− mice with respect to N3IC-tg counterparts
correlates with significant survival differences: indeed, while 75% of
N3IC-tg mice died at 24 weeks of age, displaying phenotypic
features of T-cell lymphoblastic lymphoma,7 70% of N3IC-tg/Pin1− /−
mice were still alive at the same age (Figure 4e). Less than half of
the N3IC-tg/Pin1− /− mice that died spontaneously after the age
of 18 weeks displayed tumor development at autopsy. Therefore,
N3IC-tg/Pin1− /− mice develop tumors, albeit with a reduced
kinetics, only in less than 5% of cases. Overall, these data indicate
that Pin1 deletion affects the Notch3-dependent tumor progression
and invasion properties of lymphoma cells in vivo.
Pin1 directly binds to Notch3 and influences its processing and
stability in ex vivo and in vivo systems
Pin1 isomerase is able to bind its substrates only through specific
phosphorylated Ser/Thr-Pro motifs,35 recognized by a specific
antibody (named MPM‑2).36 Notch3 intracellular region (N3IC) harbors
many of these Ser/Thr-Pro motifs, whose phosphorylation may
generate Pin1-binding sites. Indeed, by analyzing the Pin1–Notch3
interaction in vitro using a recombinant GST–Pin1, we demonstrated
that this interaction is direct (Figure 5a) and phosphorylation
dependent, as treatment with phosphatases induces loss of binding
(Figure 5b). Moreover, by using Flag-tagged Notch3-IC (Flag-N3IC)
and HA-Pin1 plasmids in co-transfection experiments, we observed
that N3IC is indeed phosphorylated in Ser/Thr-Pro motifs (Figure 5c),
as revealed by the immunoreactivity to MPM2, and both proteins
reciprocally co-immunoprecipitated (Figures 5c and d). Notch3
and Pin1 interaction occurs also in vivo, as endogenous Notch3
expressed in N3-232 T murine leukemic T cells, we established from
N3IC-tg mice,
7 was recognized by the specific MPM‑2 antibody
(Figure 5e, left panel) and was able to bind to endogenous
Pin1 protein (Figure 5e, right panel). Most importantly, endogenous
Notch3 is able to bind Pin1 also in thymocytes freshly obtained from
N3IC-tg mice (Figure 5f).
To investigate in detail the molecular mechanism by which Pin1
regulates Notch3 expression and/or function, we first analyzed
the endogenous Notch3 mRNA and protein expression levels
in thymocytes derived from wild-type (Pin1+/+) and Pin1 knockout
(Pin1− /−) mice,32 which show similar thymocyte subset distribu-
tion with respect to CD4 and/or CD8 expression (Figure 6a).
As shown in Figure 6b, despite the absence of significant
difference of Notch3 mRNA level (left panel), western blot analysis
revealed a strong increase in Notch3 protein expression in Pin1− /−
thymocytes (right panel) with respect to wt ones, as indicated by
its extracellular fragment expression (N3EC). To validate this
observation, we further analyzed the Notch3 receptor expression
at the surface of the same cells by using different techniques, that
is, FACS analysis (Figures 6c and d), western blot of membrane/
Figure 3. Pin1 ablation impairs Notch3 signaling in thymocytes of young N3IC transgenic mice resulting in the decrease of expansion/
invasiveness of CD4+CD8+ DP splenic cells. CD4+ and/or CD8+ subset distribution of thymocytes from representative 6-week-old Pin1+/+
(A), N3IC-tg (B) and N3IC-tg/Pin1
− /− (C) mice. (b) Whole-cell extracts from thymocytes illustrated in (a) were revealed with anti-Pin1,
anti-activated N3IC (N3IC-act), anti-HA (left panels) and anti-activated Notch1 (Notch1Val1744), anti-Hes1 and anti-pTα (right panels) antibodies.
Western blot against the anti-β-actin was used as a loading control. (c) CD4+ and/or CD8+ subset distribution of lymphocytes derived from SPL
and blood of representative 6-week-old Pin1+/+ (D), N3IC-tg (E) and N3IC-tg/Pin1
− /− (F) mice. (d) Sorted CD4+CD8+ (DP) splenocytes illustrated
in (c) (circle around the number) were used for western blot analysis against anti-activated N3IC (N3IC-act), anti-HA and anti-β-actin antibodies
and (e) in invasion Matrigel assay: relative percentage of DP cells invasiveness from N3IC-tg/Pin1
− /− mice is shown with respect to N3IC-tg cells.
Results are shown as the means average deviations of five independent experiments (n = 3–5 mice per group) and P-values were calculated
using Student’s T-test (i.e., **P⩽ 0.01). In all panels described in (a, c), numbers inside each cytogram indicate the percentages of the
corresponding subsets and the results are representative of five independent experiments (n= 3–5 mice per group: Pin1+/+ (n= 15), N3IC-tg
(n= 25) and N3IC-tg/Pin1− /− mice (n= 15)). THY, thymus. SPL, Spleen; PB, Peripheral Blood.
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Figure 4. Pin1-induced N3IC downregulation prevents T-ALL development and progression in N3IC transgenic mice. (a) CD4
+ and/or CD8+
subset distribution of lymphocytes derived from SPL, PB and mesenteric lymph nodes (LM) of representative 10-week-old Pin1+/+, N3IC-tg and
N3IC-tg/Pin1
− /− mice. In all panels, numbers inside each cytogram indicate the percentages of the corresponding subsets and the results
are representative of three independent experiments (n= 3–5 mice/group: Pin1+/+ (n= 9), N3IC-tg (n = 15) and N3IC-tg/Pin1− /− mice (n= 12)).
(b) Splenocytes count from Pin1+/+, N3IC-tg and N3IC-tg/Pin1
− /− mice at the age indicated. Values represent the means average deviations
of 3–5 mice for each genetic background and P-values were calculated using Student’s T-test (i.e., **P⩽ 0.01; ***P⩽ 0.001). (c) Macroscopic
aspect of SPL isolated from 20-week-old Pin1+/+ (wt), N3IC-tg (tg) and double mutant N3IC-tg/Pin1
− /− (DM) mice. (d) Histological analysis
of non-lymphoid organs (liver, upper and lung, down) from representative Pin1+/+ (wt), N3IC-tg (tg) and N3IC-tg/Pin1
− /− (DM) mice at the
age indicated. Hematoxylin and Eosin staining, original magnification × 10. (e) Mortality curve of Pin1+/+, N3IC-tg and N3IC-tg/Pin1
− /− mice.
The numbers of spontaneously dead mice were plotted against their age. Results are indicated as the percentage of surviving mice at each
age. The follow-up of mice was stopped at 24 weeks, being 75% of the N3IC-tg mice dead at this age and 70% of N3IC-tg/Pin1
− /− mice survivor
(n= 50 for Pin1+/+; n= 60 for N3IC-tg n= 30 for N3IC-tg/Pin1
− /− mice).
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cytosol fractions (Figure 6e and Supplementary Figure 4a) and
biotinylation assay (Figure 6f and Supplementary Figure 4b).
As shown in Figure 6c, Pin1− /− thymocytes display a significant
increase in the N3EC surface expression, either when the
percent distribution/mean fluorescence intensity (Figure 6c) or
the absolute number is considered (Figure 6d). Consistently, this
occurs also in the membrane fractions of the Pin1− /− thymocytes
when compared with those from Pin1+/+ littermates (Figure 6e
and Supplementary Figure 4a). The biotinylation assay shown
in Figure 6f further confirms the strong accumulation of Notch3
receptor at the cell surface of Pin1-deleted thymocytes (compare
lanes 4 and 8), in both 220-kDa (N3EC) and 97-kDa (TM-IC) Notch3
cleavage products. Since we found that the relative amounts of
Notch3 mRNA were essentially identical in both mice (Figure 6b),
we established that this accumulation could not be due to an
increased production of Notch3 but more likely to an impaired
clearance of the Notch3 receptor from the cell surface, probably
due to a defect in its processing. Indeed, N3IC levels decreased
in Pin1− /− total thymocytes of both un-biotinylated (compare
lanes 1 and 5) and biotinylated (compare lanes 3 and 7) fractions
with respect to Pin1+/+ thymocytes counterpart (Figure 6f, lower
panel, blot: N3IC high exposition and Supplementary Figure 4b).
Consistently, Notch3 intracellular domain (N3IC) was not detected
in the nucleus of Pin1− /− thymocytes (Figure 6g).
Overall, our data indicate that Pin1 is able to affect the levels
of endogenous Notch3 possibly by influencing its receptor
processing at the cell surface. In keeping with these observations,
the Pin1 ablation in N3IC-tg mice caused a significant increase
in surface Notch3 receptor per cell (Supplementary Figure 5),
as highlighted by the increase in the N3EC mean fluorescence
intensity observed in both DP thymocytes and DP splenocytes
derived from young N3IC-tg/Pin1
− /− double mutant mice described
in Figure 3, with respect to the N3IC-tg littermates.
Consistent with these data, Pin1-silenced human TALL-1 cells
showed a significant increase in N3EC protein expression (Figure 7a),
while activated-N3IC strongly decreased (Figure 7a), as previously
observed (Figure 1g). Intriguingly, we also observed a significant
decrease in N3-HA transgene expression in N3IC-tg/Pin1
− /− double
mutant mice (Figure 3b, left panel, and Figure 3d), which suggests a
role of Pin1 also directly on N3IC protein. Notably, it has been
demonstrated that Pin1 is able to affect both Notch1 processing and
stability in breast cancer context.19,20 Therefore, we analyzed the
endogenous N3IC protein stability in TALL-1 cells after Pin1 silencing
in the presence of the protein synthesis inhibitor, cycloheximide
(CHX). As shown in Figure 7b, while the N3IC protein expression
increased in the presence of CHX, necessarily generated from its cell
surface cleavage, the Pin1 silencing prevented this effect but seems
not to influence directly the N3IC half-life with respect to the control
cells, thus confirming in this context the predominant Pin1 role on
Notch3 receptor processing previously observed in ex vivo Pin1− /−
thymocytes (Figure 6). However, the addition of the proteasome
inhibitor MG132 in Pin1-silenced cells is able to rescue the N3IC
decreased expression, suggesting the involvement of the protea-
some degradation system in the regulation of N3IC protein levels
observed in the absence of Pin1. To value this possibility, avoiding
the N3IC generation from the cell surface, we used HEK293T cells
where flag-N3IC plasmid was overexpressed and endogenous Pin1
was silenced: as shown in Figure 7c, the half-life of N3IC was reduced
in Pin1-silenced cells when compared with cells silenced with the
control siRNA (Figure 7c). Overall, these data suggest that Pin1 could
have a dual role on Notch3 in T-ALL context, sustaining the cleavage
of Notch3-IC on one side and protecting it from degradation on the
other side, finally resulting in the increased intracellular levels
of Notch3IC protein.
DISCUSSION
T-ALL patients have a higher percentage of induction failure, rate
of relapse and invasion into the central nervous system,
when compared with the majority of ALL patients. An important
role of Notch signaling in the progression and aggressiveness of
solid tumors has been demonstrated;37–40 in addition, there is
increasing evidence supporting the same important role also in
leukemia.41 In particular, it has been shown that Notch1 activation
in T-ALL cells contributes to central nervous system infiltration42
and more recently that Notch1 influences both hypoxia-induced
invasion property43 and extra-medullary infiltration of T-ALLs.44
Figure 5. Pin1 directly interacts with Notch3. (a) Control or anti-Flag
antibody immunoprecipitates from HEK293T cells transfected with
Flag N3IC-wt were subjected to far western blotting using purified
GST–Pin1 as a probe, followed by anti-Pin1 immunoblotting.
Anti-Flag western blot analysis of the upper panel after stripping
is shown. (b) Lysates used in (a), previous treated with lamba
phosphatase (+), were subjected to GST or GST–Pin1 pulldown
followed by anti-Flag western blotting. The arrows indicate the
phosphorylated (upper band) and the non-phosphorylated (lower
band) forms. (c) Control or anti-Flag antibody immunoprecipitates
from HEK293T cells co-transfected with Flag N3IC-wt and HA-Pin1
plasmids were subjected to western blot and probes with anti-
MPM‑2, to detect the Notch3 phosphorylation levels at Ser/Thr‑Pro
sites, followed by stripping and anti-Flag western analysis to show
N3IC immunoprecipitated protein levels. The blot with anti-HA
antibody was used to reveal the Notch3-Pin1 binding (middle
panel). The * indicates a non-specific band. (d) Control or anti-Pin1
antibody immunoprecipitates from the same cells used in (c) were
probes with anti-Flag, to detect the Notch3-Pin1 binding, and with
the anti-HA antibody to show Pin1 immunoprecipitated protein
levels. (e) Anti-Notch3 (left panel) and anti-Pin1 (right panel)
immunoprecipitates from N3–232 T cells were subjected to western
blot and probes with anti-MPM2 antibody, to detect the Notch3
phosphorylation levels at Ser/Thr‑Pro sites, and anti-N3IC antibody
to detect endogenous Notch3–Pin1 interaction, respectively. In both
panels (e), the blots with anti-N3IC and anti-Pin1 antibodies were
used to show Notch3 and Pin1 immunoprecipitated protein levels,
respectively. (f) Anti-Pin1 immunoprecipitates from N3IC-tg thymo-
cytes were subjected to western blot and probes with anti-N3IC and
anti-Pin1 antibodies, to detect endogenous Notch3–Pin1 interaction
and Pin1 immunoprecipitated protein levels, respectively. The input
lane indicated in all the western blot of (a–d) shows 5% of total
lysate. All data are representative of at least three independent
experiments, each in triplicate. WCEs, whole-cell extracts.
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In this study, we demonstrated that Pin1, by influencing N3IC
expression and signaling, contributes to T-ALL cell invasiveness
properties both in vitro and in vivo. Indeed, we report a significant
decrease in the pro-invasive protease MMP9 levels when Notch3-
overexpressing human TALL-1 leukemic cells are inhibited for both
Notch3 and Pin1 protein expression, also confirming the known
Notch-dependent regulation of MMP expression genes.37,38,41
We genetically demonstrated that Pin1 deletion in Notch3-IC
transgenic mice blocks the expansion/invasiveness of CD4+CD8+ DP
cells in peripheral lymphoid and non-lymphoid organs and in
circulating blood, finally preventing the progression of the lympho-
proliferative disease. These results, together with previously reported
observations,13,45 confirm that the presence of CD4+CD8+ DP cells in
PB and peripheral lymphoid organs represents a characteristic
feature of T-ALL and further sustains that loss of DP in the periphery
may represent a marker of drug treatment efficiency.46
Several mechanisms regulating Notch3 expression have been
recently reported: miRNA-206 has been shown to inhibit
colon cancer cell proliferation and migration through direct
Notch3 targeting,47 as well as mir-150 does to regulate T-cell
development.48 Moreover, methylation status regulation has been
suggested to be responsible for Notch3 overexpression in T-ALL and
several solid tumors.49 Additionally, several reports have demon-
strated that Notch-IC is subjected to multiple phosphorylations in
different domains that modulate its transcriptional activity by
regulating its stability or subcellular localization14 while little is
known about PTMs of the Notch receptor and their role in
regulating Notch activity.50,51 In this study, we report for the first
time that Notch3 protein is subjected to phosphorylation in Ser/Thr-
Pro motifs and that this PTM has an effect on its interaction with
other protein, such as Pin1. Notably, more than 50% of human T-ALL
patient samples show activating Notch1 mutations9,52 whereas
overexpression of Notch3, irrespective of gross abnormalities in the
Notch3 locus, is a common finding in human T-ALL,8 raising
the possibility that in this context high Pin1 expression might
contribute to sustain high levels and function of N3IC protein,
similarly to what happens for Notch1 in breast cancer where it is
rarely mutated.20,53 Mechanistically, we show that Pin1 interacts
directly with phosphorylated Notch3 and increases N3IC protein
expression. Furthermore, we observed that both Pin1-depleted
thymocytes and splenocytes derived from Pin1− /− and/or double
mutant N3IC-tg/Pin1
− /− mice display a significant increase in the
endogenous Notch3 extracellular expression at the cell surface, thus
suggesting that the phosphorylation-dependent prolyl-isomeriza-
tion catalyzed by Pin1 may regulate Notch3 receptor processing.
More recently, an additional role of Pin1 on N1ICD stability has been
shown in breast stem cells and in neural ischemic stroke, by
protecting it from FBWX7 degradation.20,54
Figure 6. Pin1 affects Notch3 processing. (a) CD4+ and/or CD8+ subset distribution of thymocytes from Pin1+/+ and Pin1− /− mice. In both
panels, numbers inside each cytogram indicate the percentages of the corresponding subsets. (b) RT–PCR shows the unchanged relative
Notch3 mRNA levels in Pin1− /− vs Pin1+/+ thymocytes (left panel). (Right panel) Western blot analysis of whole-cell extracts (WCEs) from the
same thymocytes probed with anti-Notch3EC (N3EC) and anti-Pin1 antibodies. The β-actin expression was used as a loading control. (c) Notch3
extracellular expression (N3EC) from thymocytes of Pin1
+/+ and Pin1− /− mice indicated as percentages inside each cytogram. The violet curve
represents the isotypic control. The mean fluorescence intensity (MFI) ratio between Notch3 and isotypic control staining is also indicated. The
results showed in both panels are representative of five independent experiments (n = 5 mice for group). (d) Bar graphs represent the absolute
cell number from thymocytes expressing N3EC of the same mice indicated in (c). (e) Cytosolic (C) and membrane (M) fractions from Pin1
+/+ and
Pin1− /− thymocytes were analyzed in immunoblot assays to detect the N3EC expression. Anti-Lck and anti-α-tubulin were used as fraction
markers; anti-β-actin was used as a loading control. (f) Thymocytes from Pin1+/+ and Pin1− /− mice were incubated with EZ-Link Sulfo-NHS-SS-
Biotin (+) or were mock (− ) treated, as described in Materials and methods. Cells were lysed and extracts were loaded on a 6% SDS–PAGE gel
either directly (T fraction, 15% of the extract) or after incubation on streptavidin-agarose beads (B fraction, 85% of the extract). Extracts were
then immunoblotted with the anti-N3EC and anti-N3IC antibodies. Positions of the 210-kDa Notch3 extracellular (EC) and 97-kDa Notch3
transmembrane-intracellular (TM-IC) domains are indicated by black arrows. In the high exposition is indicated the position of the Notch3
intracellular domain (IC) (red arrow). ^ indicates non-specific bands. (g) Nuclear fractions from Pin1+/+ and Pin1− /− thymocytes were analyzed
in immunoblot assays to detect the N3IC expression. Anti-LaminB and anti-α-tubulin were used as fraction markers; anti-β-actin was used as
a loading control. In all panels (b) and (d), results are shown as the means average deviations of five separate experiments and P-values were
calculated using Student’s T-test (i.e., ns, not significant P40.05; **P⩽0.01). In all the western blots represented in the figure, FL indicates
Notch3 full-length receptor and EC indicates extracellular region.
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We have recently demonstrated that the activation of Notch
signaling decreases FBXW7 expression through the upregulation of
mir-223 in T-ALL context,55 suggesting a positive loop in sustaining
Notch-IC protein expression. Given the results reported in this
paper, we can speculate that Pin1 could reinforce this loop, as it
has been also demonstrated that Pin1 promotes FBWX7 self-
ubiquitination and its proteasomal degradation by disrupting
FBXW7 dimerization.56 Indeed, in addition to its role on Notch3
processing, in this study we also suggest a possible involvement of
Pin1 in the control of Notch3IC protein stability, which can justify the
strong decrease in the exogenous Notch3-IC, recognized by the HA
immunoreactivity, that we observed in both thymocytes and DP
splenocytes of double mutant N3IC-tg/Pin1
− /− mice, which finally
leads to the decreased levels of Notch3 target genes (pTalpha and
Hes1). Taken together, these data support the hypothesis of a
possible complex circuitry Notch3-Pin1-FBXW7 in T-ALL context,
resulting in the regulation of Notch3IC protein generation and
stability, which remains to be investigated in more detail.
Overall, our findings provide new insights unveiling a possible
dual mechanism focused on phosphorylation-dependent prolyl-
isomerization by Pin1 as responsible for sustained Notch3-IC
expression and signaling in T-cell leukemia. Notably, our data
not only extend the role of Pin1 in regulating several members
of Notch receptor family but underline the cell- (or tumor-)
dependent context of Pin1 mechanistic activity. Indeed, here we
show that in several human and mouse T-ALL models Pin1
specifically targets Notch3, without affecting Notch1 expression,
thus suggesting a possible specific role on different Notch
receptors, possibly also depending on different Pin1-target sites
involved (data not shown).
Functionally, we show that the establishment of the Pin1/Notch3
relationship may contribute to promote Notch3-induced T-ALL
aggressiveness, first by sustaining Notch3IC protein levels. Notably,
the influence of Pin1 on the Notch pathway is likely not limited to
its direct action on Notch proteins. Indeed, several Notch targets
are also Pin1 substrates (for example, cyclone D1 and NF-kB).17
This may suggest that Pin1 could promote T-ALL aggressiveness
also by enhancing the activity of some Notch3-induced Pin1
targets, such as the NF-kB transcription factor, we previously
showed to be activated by Notch357 and known to be regulated
Figure 7. Pin1 influences Notch3 processing and stability in endogenous and exogenous system. (a) Western blot analysis of Notch3
extracellular (N3EC) and activated intracellular (N3IC-act) protein expression of whole-cell extract (WCE) derived from Pin1-silenced TALL-1 (+) vs
control cells (− ) (left panel). The western blots in the figure are representative of at least three independent experiments, each in triplicate.
The optical densitometry (OD) (right panels) was analyzed in all the experiments performed, thus including the P-values, calculated using
Student’s T-test (i.e., **P⩽0.01). (b) WCEs from Pin1-silenced TALL-1 cells (+) vs control cells (− ) in a time course assay with 10 μg/ml of
cycloheximide (CHX), in the presence or absence of the proteasome inhibitor MG132 for the same times before lysis, were revealed by
immunoblotting with anti-activated N3IC (N3IC-act), anti-Pin1 and anti-β-actin antibodies (left panel). The right panel shows the relative
quantification of activated-N3IC as determined by OD. (c) Left panel, Western blot analysis of whole-cell extracts from HEK293T cells
transfected with Flag N3IC-wt plasmid and silenced for Pin1 (+) or control (− ) in a time course assay with 10 μg/ml of cycloheximide (CHX).
Extracts were immunoblotted with anti-Flag, anti-Pin1 and anti-β-actin antibodies. The right panel shows the relative quantification of Flag
N3IC as determined by OD. All data are representative of at least three independent experiments, each in triplicate.
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by Pin1 isomerase also in leukemia/lymphoma development.58
In this way, Pin1 blocking may represent a new approach for
targeting a common oncogenic mechanism to stop the multiple
cancer-driving pathways, which act simultaneously in the disease.
Indeed, more recently, it has been demonstrated that the Pin1
downmodulation by ATRA (all-trans-retinoic acid), known to be
used in acute promyelocytic leukemia (APL) therapy,59 correlates
with tumor cell growth inhibition in APL animal models and
human APL cells in vitro as well as in APL patients.60 Notably,
this occurs also in triple negative breast cancer, thus exerting
a potent anticancer activity, probably by blocking Pin1 substrate
oncogenes and tumor suppressors at the same time.60 In keeping
with these findings, our work underlines for the first time that Pin1
isomerase could represent a new potential therapeutic target also
in T-ALL treatment, by the regulation of Notch3 cancer-driving
pathway. The significant direct correlation observed between Pin1
and Notch3 expression levels in human T-ALL cell lines and
primary tumor samples confirms the possible relevance of our
observations for human T-ALL development.
Our findings identify novel molecular mechanisms involved
in the invasion of T-ALL cells. These results may provide a rationale
for novel therapy approaches, as combined inhibition of Pin1 and
Notch3 could suppress aggressive phenotypes, representing
a useful tool to interfere with the mechanisms governing T-ALL
cell extravasation into lymphoid and non-lymphoyd tissues, finally




− /− double mutant mice were generated by crossing N3IC-tg
mice7 with Pin1− /−mice.32 All mouse strains were on a C57BL/6 background.
In all the experiments including mice studies at least nine animals for each
genotype were used. The exact number of mice used in each experiment
was reported in the relative figure legend. Different experimental groups
were based on the age and genotype of the animals. No mice were excluded
during the experiments. The studies involving animals have been conducted
following the Italian National Guidelines for Animal Care, established in DL
No. 26, 2014 and in accord with the Directive 2010/63/UE.
Cell culture and treatments
HEK293T, murine N3-232T7 and human leukemic cells (Molt3, SilAll, p12-l,
Jurkat and TALL-1)55,61 were maintained as described elsewhere and all
are mycoplasma-free. Cells were treated with 10 μM of GSI IX (DAPT)
(Calbiochem, Darmstadt, Germany; Cat#565770) for 24 h. In some cases,
TALL-1 cells were treated with: 30 μM proteasome inhibitor MG132 (Sigma,
St Louis, MO, USA; Cat#C2211); 10 μg/ml ribosome inhibitor cycloheximide
(Sigma; Cat#C4859) for the times indicated; 10 μg/ml of blocking anti-human
Notch3 antibody (R&D Systems, Minneapolis, MN, USA; Cat#AF1559) for 48 h.
Purified Sheep IgG (R&D Systems; Cat#5-001-A) was used as an isotype control.
Phosphatase treatment, in vitro binding, immunoprecipitation,
western blot, far western and biotinylation assay
λ-Phosphatase treatment,19 GST pull down,19 far western,19 protein extracts
preparation,12 immunoprecipitation,12 immunoblotting assays12 and bioti-
nylation assay12,62 were performed as previously described. Immunoblot
analysis was performed using the following antibodies: anti-Flag (Sigma,
Cat#F3165), anti-Flag-HRP (Sigma; Cat#A8592), anti-MPM2 (05-368, Millipore),
anti-Notch1Val1744 (Cell Signaling, Danvers, MA, USA, Cat#2421), anti-Notch3
(Cell Signaling; Cat#2889); anti-Notch3 M20 (Santa Cruz Biotechnology,
Dallas, TX, USA, Cat# sc-7424), anti-Pin1 (Santa Cruz Biotechnology;
Cat#sc-46660), anti-β-actin (Santa Cruz Biotechnology; Cat#sc-47778),
anti-Lck (Santa Cruz Biotechnology; Cat#sc-433), anti-α-tubulin (Santa
Cruz Biotechnology; Cat#sc-803), anti-LaminB M20 (Santa Cruz Biotech-
nology; Cat#sc-6217) and anti-Hes1 (Santa Cruz Biotechnology; Cat#sc-
25392). The antibody against the activated Notch3-IC protein (N3IC-act)
was kindly provided by Genentech (South San Francisco, CA, USA). The
anti-N3EC (5E1) antibody was kindly provided by Professor A Joutel.
62 The
anti-pTα antibody was kindly provided by H von Bohemer.63
Matrigel invasivity assay
To test the invasion ability, we used Matrigel Invasion Chamber (Corning,
Tewksbury, MA, USA; Cat# 354480), as described elsewhere.31 Briefly, 18–24 h
before transfection (for siRNA experiments), we plate TALL-1 cells at
exponential phase in medium 10% FCS plus antibiotics, as recommended
by the Neon Trasfection System used for Pin1 silencing. The day after,
we silenced Pin1 for 72 h following the Neon manufacturer’s instructions and
12 h before the harvesting of the cells, we prepared the Matrigel Invasion
Chamber according to the manufacturer’s istructions; then, after cell
counting we loaded 2.5 ×105 cells into each column (at a final concentration
of 0.5× 106/ml) in medium with low serum. All samples were loaded in
triplicate. After 12 h in the incubator at 37 °C, we harvested the cells by
recovering the Invasive cells, I (which were passes throught the matrigel until
the complete medium) and the Non-Invasive cells, NI (which were retained in
the upper space of the chamber). After counting, we proceeded with two
type of analysis, obtaining the same results: (a) % invasiveness = [I/total cell
count (I+NI)] × 100; (b) % invasiveness = (I/NI) × 100.
For invasion experiments on CD4+CD8+ DP splenocytes sorted from
N3IC-tg and N3IC-tg/Pin1
− /− mice, we proceeded with the same protocol
described above after cell sorting; 24 h into Matrigel columns before
harvesting was considered.
Subcellular fractionations
Cytoplasmic-membrane and nuclear-cytosol fractionations were per-
formed as described elsewhere.12,64
Histological analysis
Non-lymphoid organs were formalin fixed and paraffin embedded.
Consecutive sections (5–6 μm thick) were stained with Hematoxylin and
Eosin and observed under light microscopy. The analysis was conducted
blindly.
Cell transfections and plasmids
Transient transfections were performed by Lipofectamine-2000 Kit
(Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instruc-




Total RNA extraction and reverse transcription PCR (RT–PCR) were
previously described.55 The expression levels of MMP9 and GAPDH mRNA
were determined by TaqMan quantitative real-time RT–PCR (qRT–PCR)
performed on cDNA according to the manufacturer's instructions (Applied
Biosystems, Life Technologies Brand, Carlsbad, CA, USA) and using the ABI
Prism 7900HT (Applied Biosystems). Data were analyzed by the ΔΔCt
method, and GAPDH was used to normalize the expression levels of mRNA.
siRNA silencing
Cells were transfected with 20 nM siRNAs anti-Notch3 (Santa Cruz Biotechnol-
ogy; Cat#sc-37135) or Pin1 (Santa Cruz Biotechnology; Cat#sc-36230) and the
corresponding control scrambled siRNAs (Santa Cruz Biotechnology; Cat#sc-
37007) using Neon transfection System (Life Technologies; Invitrogen)
following the manufacturer’s recommendations. Cells were analyzed 48 or
72 h after transfection.
In silico analysis of patient and T-ALL cell lines deposited data
Bone marrow or PB samples from a cohort of 117 pediatric T-ALL patient,
deriving from different molecular cytogenetic T-ALL subgroups samples,26
and a group of 41 human T-ALL cell lines from three Oncomine datasets23–25
were analyzed for the correlation between Pin1 and Notch3. The expression
values of Notch3 and Pin1 were filtered in each analysis utilizing the
expression probe set 203237_s_at representing Notch3 and the expression
probe set 202927_s_at representing Pin1. The expression value of Notch3
and Pin1 is given in log2 scale after normalizing data with the RMA
algorithm.26 The index Pearson R expresses the linear relation between
paired samples, and P-values were calculated using Student’s T-test.
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Fluorescence-activated cell sorting analysis
Freshly isolated cells from thymi, SPL, blood and lymph nodes were prepared
and stained, as previously described,65 and analyzed on an FACS-Calibur with
CellQuest software (BD-Biosciences, San Jose, CA, USA). Cells were stained with
APC-CD4 and PE-CD8-conjugated mAbs (BD-PharMingen, San Diego, CA, USA).
For Notch3 extracellular staining, cells were incubated with murine Notch3
antibody (R&D Systems; Cat#AF1308) or normal goat IgG (R&D Systems;
Cat#AB-108-C) used as a negative control. Cell sorting of Total RNAD4+CD8+
DP splenocytes suspensions from N3IC-tg and N3IC-tg/Pin1
− /− mice was
obtained as described elsewhere.55
Statistical analysis
Results were reported as the mean± s.d. A Student's t-test for paired
samples was used to assess differences among groups. For multiple
comparisons of groups, one-way analysis of variance was used. Among the
groups that we have statistically compared we observed similar variance.
A P-value of ⩽ 0.05 was considered as statistically significant (*P⩽ 0.05;
**P⩽ 0.01 and ***P⩽ 0.001). In some cases, the index Pearson R is also
indicated to express a possible linear relation between paired samples. All
data shown are representative of at least three independent experiments,
and the repeat number was increased according to effect size or sample
variation. We estimate the sample size considering the variation and mean
of the samples. No statistical method was used to predetermine sample
size. No animals or samples were excluded from any analysis.
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